[Exudative onycholysis and acute bacterial paronychia related to BIBF-1120 and paclitaxel: response to topical therapy].
A case of a 50 years-old breast cancer patient treated with weekly paclitaxel and BIBF 1120 is reported herein. At the end of the twelfth cycle of chemotherapy, the patient developed distal onycholysis with intense hyponychium serous exudates, pain and malodor in all her fingernails. It was treated with topical fusidic acid and 1% methylprednisolone aceponate two times daily, with an excellent clinical response from the first three days of treatment. Bacterial paronychia with nail plate loss of the fifth left fingernail was observed a week after the topical therapy was started, with positive cultures for Methicillin susceptible Staphylococcus aureus. There are few reported cases of exudative onycholysis associated with chemotherapy. However, these are especially related to paclitaxel. No recurrences of nail disturbances were observed weeks after the end of chemotherapy. Topical corticosteroids and fusidic acid could be considered as a therapeutic option when exudative onycholysis related to paclitaxel is established
Azael
A
Freites-Martínez
Diego
D
Martinez-Sánchez
Nieves Puente
NP
de Pablo
Angélica
A
Calderón-Komaromy
Susana
S
Córdoba
Jesús
J
Burbujo
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy*; D004198:Disease Susceptibility; D005260:Female; D005672:Fusidic Acid / Q000627:therapeutic use; D006225:Hand; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects*; D008775:Methylprednisolone / Q000031:analogs & derivatives / Q000627:therapeutic use; D008875:Middle Aged; D054039:Onycholysis / Q000139:chemically induced* / Q000150:complications / Q000188:drug therapy / Q000382:microbiology; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects*; D010304:Paronychia / Q000139:chemically induced* / Q000188:drug therapy / Q000382:microbiology; D013207:Staphylococcal Skin Infections / Q000188:drug therapy / Q000209:etiology* / Q000382:microbiology
D020533:Angiogenesis Inhibitors; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000972:Antineoplastic Agents, Phytogenic; D007211:Indoles; D005672:Fusidic Acid; C078007:methylprednisolone aceponate; C530716:nintedanib; D017239:Paclitaxel; D008775:Methylprednisolone